Gilead Sciences, Inc. (GILD) $133.92
Gilead is charging toward its 52-week highs, but a cooling RSI and looming earnings on August 7th suggest the easy money has already been made in this leg.
52-wk High $157.29
📌 Investment Snapshot
- Trading at $133.92 with a 18.2x P/E, GILD offers a 2.49% dividend yield for income-focused portfolios.
- Q1 2026 revenue hit $6.96B with $1.63 EPS, showing steady recovery in the oncology segment.
- Technical Confluence Score of 80/100 reveals strong institutional support at the $125.90 VWAP level.
- Wall Street consensus remains bullish with a $158.30 mean target, implying double-digit upside.
⏳ WAIT
Gilead has successfully filled its bearish FVG at $133.27, yet the RSI of 65.3 warns of diminishing momentum. While the long-term setup is robust, the proximity to earnings creates an unfavorable risk-reward for new entries today.
| 📍 Entry Zone | $126.50 or below | 🛑 Stop-Loss | $119.50 |
| 📋 Adjust If | Q2 earnings beat exceeds 15% revenue growth | ||
The Investment Case — Why Now?
Over the last 90 days, Gilead has pivoted from a stagnant HIV-legacy play into a diversified oncology contender. The market is finally pricing in the scalability of its cell therapy pipeline, evidenced by the 5.3% gain this month. Institutional accumulation by Blackrock and Vanguard underscores a shift toward defensive healthcare assets as macro volatility persists.
The primary risk remains the $166.3B market cap ceiling if clinical trials for Trodelvy face regulatory headwinds. A failure to maintain the $129 SMA50 support could trigger a slide back to the $107.75 lows. Can Gilead’s oncology growth outpace the natural revenue decay of its aging HIV portfolio?
🤔 Can Gilead’s oncology growth outpace the natural revenue decay of its aging HIV portfolio?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers – General |
| Dividend Yield | 2.49% |
| Short Float | 2.0% |
Open chart on TradingView →
📈 Price Action & Technicals
Golden Cross
Inside VA
Sell-side Sweep at $128.2 on 2026-06-26
The stock currently trades above both its SMA50 and SMA200, which are converged at $129.43. This rare alignment confirms a powerful base of support but suggests the current price is extended from the mean. A retest of this $129 level is likely before any sustainable move toward $150.
RSI at 65.3 signals that buyers are in control, though the ADX of 31.9 warns the trend is becoming overextended. The MACD golden cross remains active, yet the histogram is beginning to flatten. We expect a period of consolidation as the stock digests recent gains.
The Anchored VWAP at $125.90 serves as the definitive ‘line in the sand’ for institutional bulls. Volume Profile shows a Point of Control at $123.20, indicating significant historical transacting at lower levels. Price is currently testing the upper boundary of the Value Area ($137.99).
Recent liquidity sweeps at $128.20 suggest that ‘smart money’ cleared out weak hands before this latest leg up. The filling of the bearish FVG at $133.27 removes a key overhead obstacle. However, the low volume ratio of 0.27x indicates this move lacks the conviction of a major breakout.
Historically, GILD tends to trade sideways in the three weeks leading up to August earnings. Without a fresh catalyst, the stock is likely to gravitate back toward the $128 support zone. We advise staying on the sidelines until the RSI cools below 50 or the price hits our entry zone.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| GILD | Gilead Sciences | 18.2x |
| ABBV | AbbVie Inc. | 22.5x |
| AMGN | Amgen Inc. | 19.8x |
| PFE | Pfizer Inc. | 14.1x |
| SPY | S&P 500 Avg | 21.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $6.96B | $1.63 | +4.2% |
| Q4 2025 | $7.92B | $1.76 | +3.8% |
| Q3 2025 | $7.77B | $2.46 | +12.1% |
| Q2 2025 | $7.08B | $1.57 | +2.5% |
Gilead generated $2.4B in free cash flow last quarter, supporting $0.4B in buybacks and a stable dividend.
Revenue growth has been lumpy but generally positive, driven by the oncology portfolio. The market is looking for EPS stability above $1.70 in the upcoming August report to justify a P/E expansion toward 20x.
🚀 Growth Drivers — What Moves the Stock
- Oncology Expansion 🟢 Upside Surprise — Trodelvy and cell therapy sales are becoming a larger slice of the revenue pie, reducing HIV dependence.
- Liver Disease Pipeline 🟡 Priced In — Advancements in NASH and Hepatitis treatments provide a long-term floor for valuation.
🤔 Will the August 7th earnings report provide the ‘beat and raise’ needed to break $140?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 119,010 |
| Vanguard Capital Management LLC | 80,654 |
| FMR, LLC | 71,906 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| O'DAY DANIEL PATRICK | Chief Executive Officer | 2026-07-01 | Purchase | 15000 |
| DICKINSON ANDREW D | Chief Financial Officer | 2026-06-15 | Purchase | 3000 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 2.0% | 2.7 |
⚠ Key Risk Factors
~$4B impact
~$1.5B impact
🎯 Guidance & Wall Street View
Management has signaled a focus on operational efficiency and pipeline execution for the remainder of 2026.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $180.00 | $158.30 | $120.00 | 27 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Morgan Stanley | Overweight | $165 | 2026-07-08 | Maintained |
| HSBC | Buy | $160 | 2026-07-06 | Upgrade |
Analysts are overwhelmingly positive, with the mean target suggesting 18% upside. The recent HSBC upgrade signals growing confidence in the oncology pivot.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Oncology revenue grows >20% YoY.
- Successful Phase 3 data for pipeline candidates.
📊 Base Case
Gilead maintains market share in HIV while slowly scaling oncology, leading to steady P/E expansion.
🐻 Bear Case
- Regulatory setbacks for key pipeline drugs.
- HIV revenue declines faster than oncology can scale.
🎯 Investor Action Plan — By Profile
The RSI is too hot for a fresh entry. Wait for a pullback to the $128.20 liquidity sweep zone before playing the run into earnings.
Maintain current positions. The technical confluence score of 80/100 suggests the trend is healthy, but adding here increases your cost basis unnecessarily.
For those with a 3-year horizon, the 2.49% yield and 18.2x P/E represent a fair entry into a diversifying biotech giant.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: When is Gilead's next earnings report?
Gilead is scheduled to report its Q2 2026 earnings on August 7, 2026.
Q: Is Gilead's dividend safe?
Yes, with $2.4B in quarterly free cash flow and a payout ratio well within historical norms, the 2.49% yield is secure.
Q: What is the key technical level to watch?
The $129.43 level is critical, as it represents the confluence of the SMA50 and SMA200.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investing in biotech involves significant risk due to clinical trial outcomes and regulatory changes.
All active positions and their real-time performance are tracked on our Investment Log.
#GILD #Gilead #Biotech #StockMarket #Investing #WallStreet #Healthcare #Dividends